Skip to content
Press Releases
Filter Releases
 
Press Releases
Apr 26, 2017
SOUTH SAN FRANCISCO, Calif., April 26, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced that new data demonstrating the strong performance of the Afirma Gene Expression Classifier (GEC) in thyroid canc...
PDF
Apr 19, 2017
SOUTH SAN FRANCISCO, Calif., April 19, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its first quarter 2017 financial results after close of market on Wednesday, May 3, 2017. Following the announcement, Veracyte's management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss th...
PDF
Apr 3, 2017
SOUTH SAN FRANCISCO, Calif., April 3, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced that multiple studies supporting the use of the company's Afirma Gene Expression Classifier (GEC) in thyroid cance...
PDF
Mar 23, 2017
SAN FRANCISCO, March 23, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced that multiple presentations demonstrating the clinical utility of the Afirma Gene Expression Classifier (GEC) in thyroid cancer...
PDF
Mar 1, 2017
SOUTH SAN FRANCISCO, Calif., March 1, 2017 /PRNewswire/ -- Revenue Grew 31%, to $65.1 Million in 2016 Full-Year Afirma® GEC Volume Increased 20%, to 23,237 Tests Conference Call and Webcast Today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ: VCYT) today announced financial results and business progress for the quarter ...
PDF
Feb 28, 2017
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced two key executive leadership promotions. Christopher M. Hall has been named president and chief operating officer ...
PDF
Feb 27, 2017
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2017  /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, announced that data published for the first time today in the Journal of the National Cancer Institute (JNCI) demonstrate the pot...
PDF
Feb 21, 2017
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, today announced that ten Blues plans have recently issued new positive coverage policies for the Afirma Gene Expression Classifier...
PDF
Feb 15, 2017
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that it will report its fourth quarter and full-year 2016 financial results after close of market on Wednesday, March 1, 2017. Following the announcement, Veracyte's management will host a live conference call and webcast at 4:30 p.m. Eastern Ti...
PDF
Feb 8, 2017
SOUTH SAN FRANCISCO, Calif., Feb. 8, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, will extend access to its Afirma Gene Expression Classifier (GEC) through an agreement with Quest Diagnostics (NYSE: DGX), the worl...
PDF
Page:
...
Next Last